Nanoformulations of natural products for management of metabolic syndrome

被引:73
作者
Taghipour, Yasamin Davatgaran [1 ,2 ,3 ]
Hajialyani, Marziyeh [4 ]
Naseri, Rozita [5 ]
Hesari, Mahvash [6 ]
Mohammadi, Pantea [6 ]
Stefanucci, Azzurra [7 ]
Mollica, Adriano [7 ]
Farzaei, Mohammad Hosein [4 ]
Abdollahi, Mohammad [8 ,9 ]
机构
[1] Tabriz Univ Med Sci, Sch Adv Med Sci, Dept Med Nanotechnol, Tabriz, Iran
[2] USERN, Phytopharmacol Interest Grp PPIG, Tehran, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Kermanshah Univ Med Sci, Hlth Inst, Pharmaceut Sci Res Ctr, Kermanshah, Iran
[5] Kermanshah Univ Med Sci, Internal Med Dept, Fac Med, Kermanshah, Iran
[6] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran
[7] G dAnnunzio Univ Chieti Pescara, Dept Pharm, I-66100 Chieti, Italy
[8] Tehran Univ Med Sci, Toxicol & Dis Grp, Inst Pharmaceut Sci TIPS, Tehran 1417614411, Iran
[9] Tehran Univ Med Sci, Fac Pharm, Tehran 1417614411, Iran
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2019年 / 14卷
关键词
nanoformulation; natural products; metabolic syndrome; diabetes; ACTIVATED RECEPTOR-GAMMA; INSULIN-RESISTANCE; LIPID-METABOLISM; NUCLEAR RECEPTORS; IN-VITRO; ENDOTHELIAL FUNCTION; STEVIA-REBAUDIANA; SILYBUM-MARIANUM; OXIDATIVE STRESS; PROTEIN-KINASE;
D O I
10.2147/IJN.S213831
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Metabolic syndrome is a common metabolic disorder which has become a public health challenge worldwide. There has been growing interest in medications including natural products as complementary or alternative choices for common chemical therapeutics regarding their limited side effects and ease of access. Nanosizing these compounds may help to increase their solubility, bioavailability, and promisingly enhance their efficacy. This study, for the first time, provides a comprehensive overview of the application of natural-products-based nanoformulations in the management of metabolic syndrome. Different phytochemicals including curcumin, berberine, Capsicum oleoresin, naringenin, emodin, gymnemic acid, resveratrol, quercetin, scutellarin, stevioside, silybin, baicalin, and others have been nanosized hitherto, and their nanosizing method and effect in treatment and alleviating metabolic syndrome have been reviewed and discussed in this study. It has been discovered that there are several pathways or molecular targets relevant to metabolic disorders which are affected by these compounds. Various natural-based nanoformulations have shown promising effect in treatment of metabolic syndrome, and therefore can be considered as future candidates instead of or in conjunction with pharmaceutical drugs if they pass clinical trials successfully.
引用
收藏
页码:5303 / 5321
页数:19
相关论文
共 158 条
  • [91] Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease
    Meyer, MM
    Levin, K
    Grimmsmann, T
    Beck-Nielsen, H
    Klein, HH
    [J]. DIABETOLOGIA, 2002, 45 (06) : 813 - 822
  • [92] Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome
    Miller, AR
    Etgen, GJ
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (09) : 1489 - 1500
  • [93] The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases
    Mitjavila, M. T.
    Moreno, J. J.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2012, 84 (09) : 1113 - 1122
  • [94] The Metabolic Syndrome and Cardiovascular Risk A Systematic Review and Meta-Analysis
    Mottillo, Salvatore
    Filion, Kristian B.
    Genest, Jacques
    Joseph, Lawrence
    Pilote, Louise
    Poirier, Paul
    Rinfret, Stephane
    Schiffrin, Ernesto L.
    Eisenberg, Mark J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (14) : 1113 - 1132
  • [95] Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment
    Mukhopadhyay, Piyasi
    Maity, Subhajit
    Mandal, Sudipto
    Chakraborti, Abhay Sankar
    Prajapatia, A. K.
    Kundu, P. P.
    [J]. CARBOHYDRATE POLYMERS, 2018, 182 : 42 - 51
  • [96] Ochin Chinedu C., 2018, Cardiovascular & Hematological Disorders - Drug Targets, V18, P61, DOI 10.2174/1871529X18666180201130340
  • [97] Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation
    Ortiz-Andrade, R. R.
    Sanchez-Salgado, J. C.
    Navarrete-Vazquez, G.
    Webster, S. P.
    Binnie, M.
    Garcia-Jimenez, S.
    Leon-Rivera, I.
    Cigarroa-Vazquez, P.
    Villalobos-Molina, R.
    Estrada-Soto, S.
    [J]. DIABETES OBESITY & METABOLISM, 2008, 10 (11) : 1097 - 1104
  • [98] Patel K., 2012, ASIAN PAC J TROP DIS, V2, P414, DOI [DOI 10.1016/S2222-1808(12)60090-5, 10.1016/S2222-1808(12)60090-5]
  • [99] Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes
    Patel, Tushar P.
    Rawal, Komal
    Bagchi, Ashim K.
    Akolkar, Gauri
    Bernardes, Nathalia
    Dias, Danielle da Silva
    Gupta, Sarita
    Singal, Pawan K.
    [J]. HEART FAILURE REVIEWS, 2016, 21 (01) : 11 - 23
  • [100] Comparative prophylactic effects of α-eleostearic acid rich nano and conventional emulsions in induced diabetic rats
    Paul, Debjyoti
    Dey, Tanmoy Kumar
    Mukherjee, Sayani
    Ghosh, Mahua
    Dhar, Pubali
    [J]. JOURNAL OF FOOD SCIENCE AND TECHNOLOGY-MYSORE, 2014, 51 (09): : 1724 - 1736